FGF-23 is a protein of ∼30 kDa that is proteolytically processed to generate smaller N-terminal (18 kDa) and C-terminal (12 kDa) fragments. The N-terminal fragment of FGF-23 contains the FGF receptor (FGFR)-binding domain. In vivo studies using synthetic peptides have indicated that neither of the processed N-terminal or C-terminal fragments of FGF-23 can influence serum phosphate levels. FGF-23 can decrease the activity of NaPi-2a and NaPi-2c cotransporters to reduce renal phosphate reabsorption and thereby can increase urinary phosphate excretion. Similarly, FGF-23 can suppress the expression of 1-alpha-hydroxylase to reduce the production of the active vitamin D metabolite 1,25(OH)2D. Moreover, FGF-23 can also induce 24- hydroxylase, which degrades 1,25(OH)2D
Aliases- FGF-23, Phosphatonin, Tumor-derived hypophosphatemia-inducing factor, HYPF
- Recombinant Human Fibroblast Growth Factor 23 (FGF23)
Formulation- Recombinant Human FGF23 was lyophilized from 0.2 µm filtered PBS solution, pH 7.4.
Endotoxin Level- <1.0 EU/µg of recombinant protein as determined by the LAL method.
Storage Condition- The lyophilized protein is stable for at least one year from date of receipt at -70°C. Upon reconstitution, this cytokine can be stored in working aliquots at +2° to +8°C for one month, or at -20°C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.